SCHEMBL2370538

SCHEMBL2370538

CC(C(=O)O)c1ccc(N2CCN(C)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
TP53 P04637 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 2/20 0.50
GAA P10253 3/20 0.49
HDAC3 O15379 3/20 0.49
HDAC8 Q9BY41 3/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C19 P33261 1/20 0.49
PGR P06401 1/20 0.49
CYP3A4 P08684 1/20 0.49
PKM P14618 1/20 0.49
NFKB1 P19838 1/20 0.49
DRD1 P21728 1/20 0.49
HTT P42858 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27741267 0.88 NPC1 (0.51) NPC1RAB9ATP53SMN1; SMN2LMNA
SCHEMBL6787925 0.86 MAPT (0.53) NPC1RAB9ATP53SMN1; SMN2LMNA
SCHEMBL2369973 0.85 ALDH1A1 (0.51) NPC1RAB9ATP53SMN1; SMN2LMNA
SCHEMBL27602621 0.85 ALDH1A1 (0.51) NPC1RAB9ATP53SMN1; SMN2LMNA
SCHEMBL5217432 0.83 ALDH1A1 (0.55) NPC1RAB9ATP53SMN1; SMN2LMNA
SCHEMBL5217443 0.83 ALDH1A1 (0.55) NPC1RAB9ATP53SMN1; SMN2LMNA
SCHEMBL11492371 0.82 ALDH1A1 (0.51) NPC1RAB9ATP53SMN1; SMN2LMNA
SCHEMBL5332118 0.82 ALDH1A1 (0.54) NPC1RAB9ATP53SMN1; SMN2LMNA
SCHEMBL11063989 0.81 PTGS1 (0.60) NPC1RAB9ATP53SMN1; SMN2LMNA
SCHEMBL3156564 0.80 NPC1 (0.49) NPC1RAB9ATP53SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150272947-A1 INHIBITORS OF PROTEIN KINASES ASTRAZENECA AB (SE) 2015-10-01 US disclosed
US-9067888-B2 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2015-06-30 US disclosed
CN-102834380-B Inhibitors of protein kinases ASTRAZENECA 2015-04-01 CN disclosed
US-20130345233-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2013-12-26 US disclosed
US-8518948-B2 Inhibitors of protein kinases INGENIUM PHARMACEUTICALS GMBH (DE) 2013-08-27 US disclosed
EP-2545037-A1 INHIBITORS OF PROTEIN KINASES Ingenium Pharmaceuticals GmbH (DE) 2013-01-16 EP disclosed
CN-102834380-A Inhibitors of protein kinases INGENIUM PHARMACEUTICALS GMBH 2012-12-19 CN disclosed
US-20110224225-A1 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2011-09-15 US disclosed
WO-2011110612-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345233-A1 INHIBITORS OF PROTEIN KINASES CDK1, CDK2, CDK3 NPC1 4514/4885RAB9A 2112/4885TP53 1904/4885
US-20150272947-A1 INHIBITORS OF PROTEIN KINASES CDK1, CDK2, CDK3 NPC1 4514/4885RAB9A 2112/4885TP53 1904/4885
US-20110224225-A1 Inhibitors of protein kinases CDK1, CDK2, CDK3 NPC1 4514/4885RAB9A 2112/4885TP53 1904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.